Almost a third of the world's population is infected with the causative agent of tuberculosis, Mycobacterium tuberculosis. Close to 10% may actually develop the disease at some point in their life. Despite the already existing treatments that, together with the early diagnosis, are able to treat and prevent the disease, what is certain is that the duration of the treatment regimens associated with their non-compliance has potentiated the appearance of resistant, multiresistant and extremely resistant strains that hinder against tuberculosis. That's why Tecnimede - Sociedade Técnico-Medicinal SA is promoting and developing a project for the identification, optimization and repositioning of compounds for the treatment of Tuberculosis (PROMYCO II), with the specific objective of identifying a leading compound or family of compounds that may constitute a future therapeutic agent in the treatment of diseases caused by Mycobacterium tuberculosis and other mycobacteria.
More than 300 new chemical entities have been already synthesized by the Tecnimede Group and tested against laboratory strains and clinics of Mycobacterium tuberculosis in the replicative state. So far, about 30 molecules have been identified. The PROMYCO II project fits into the areas of "Health" and "Biotechnology", setting the work to be developed in the "Technologies for Quality of Life" platform. More specifically, the aim of this project is to "Develop new (pharmacological) treatments and therapies" using "pre-clinical research platforms".
In addition, Tecnimede Group, as a promoter of this project, sought to endogenise methodologies for the organization and management of technical-scientific skills related to the earliest stages of drug discovery and development.
This project is co-funded by COMPETE (Operational Program for Competitiveness and Internationalization), PORTUGAL 2020; European Regional Development Fund – European Union.